Recap: Perrigo Q2 Earnings

Shares of Perrigo PRGO rose 0.9% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 19.77% over the past year to $1.03, which beat the estimate of $0.88.

Revenue of $1,219,000,000 rose by 8.16% from the same period last year, which missed the estimate of $1,240,000,000.

Guidance

Earnings guidance hasn't been issued by the company for now.

Revenue guidance hasn't been issued by the company for now.

How To Listen To The Conference Call

Date: Aug 05, 2020

Time: 09:00 AM

ET Webcast URL: https://investor.perrigo.com/events-webcasts

Technicals

Company's 52-week high was at $63.86

52-week low: $40.01

Price action over last quarter: Up 5.58%

Company Description

Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to over the counter and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focus on consumer wellness in conjunction with the divestiture of animal health, acquisition of Ranir Global Holdings, and plans to sell or spin off the prescription business.